

Corporate Office:

2nd Floor, Premdeep Building, Above Latur Urban Co-op. Bank Ltd.,
Lulla Nagar Chowk, Camp Kondhwa Road, Pune - 411 040.
(Maharashtra) INDIA, Tel.: +91-20-41471234
Email: enquiry@cian.co, cianhealthcare@yahoo.co.in
Web: www.cian.co

Registered Office:

Milkat No. 16431, Block No. 1 from South Side, C.S. No. 227/10 3B,
Harpale Park, Opp. Berger Paint, Phursungi, Tal. Haveli, Dist. Pune - 412 308,
(Maharashtra) INDIA. Tele-Fax.: +91-20-26982792

Factory:

Kh. No.: 248, Village Sisona, Bhagwanpur, Roorkee, Haridwar,
Pin - 247 661. Uttarakhand, Tel.: 1332 235352

CIN: L24233PN2003PLC017563

To,
BSE Limited – CRD
P.J. Towers, Dalal Street,
Fort, Mumbai-400001

Date: 13.11.2020

Script Code: 542678

Sub: OUTCOME OF BOARD MEETING.

Ref: Regulation 30(6) & 30(2) of (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In pursuance of the SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015 ('Listing Regulations'), please be informed that the Board of Directors at its meeting held today i.e., Friday, November 13, 2020, has inter alia considered and approved the Un-Audited Financial Results (standalone and consolidated) for the quarter and half year ended September 30, 2020 and took on record the Limited Review Report issued by the Statutory Auditors of the Company.

The aforesaid Board Meeting commenced at 12:30 PM and concluded at 02:30 PM on November 13, 2020.

Please take the same on your record and oblige.

For Cian Healthcare Limited


Yashi Gupta
Company Secretary

Encl.: As above





Agarwal Mahesh K. & Co.
Chartered Accountants

📍 : Flat No. 19, Hansmani Society, Behind Parvati Petrol Pump
Near Dandekar Bridge, Pune 411030, Maharashtra
✉ : agarwalmaheshkca@gmail.com
🌐 : www.agarwalmahesh.com
☎ : +91 9028109491, 9766909029

Limited Review Report on unaudited half yearly and year to date Financial Results of the Cian Healthcare Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors
Cian Healthcare Limited


We have reviewed the accompanying statement of unaudited standalone financial results of Cian Healthcare Limited ('the Company') for the half year ended September 30, 2020 and for the year-to-date results for the period from April 1, 2020 to September 30, 2020 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').

This statement is the responsibility of the Company's Management and has been approved by the Board of directors and statement has been prepared in accordance with the recognition and measurement principles laid down in AS 25 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to Believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Agarwal Mahesh K. & Co.
Chartered Accountants


CA Sunny Boundia
Partner
FRN: 008007C
Membership No. 164172
Date: 13.11.2020
UDIN:- 20164172AAAABB1327
Pune




BRANCHES

MUMBAI | KOLHAPUR | SATNA | GULBARGA | JAMSHEDPUR | PATNA | RANCHI

CIAN HEALTHCARE LIMITED
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,
C.S.NO.227/2+3A, HARPALE PARK, OPP. BERGER PAINT
PHURSUNGI, TAL. HAVELI, DIST. PUNE-412308
CIN: L24233PN2003PLC017563

STATEMENT OF STANDALONE PROFIT AND LOSS FOR THE HALF YEAR ENDED ON 30.09.2020

Particulars	For the half year ended September 30, 2020	For the year ended March 31, 2020	For the half year ended September 30, 2019
	Unaudited	* Audited	Unaudited
	Rs. (in Lakhs)	Rs. (in Lakhs)	Rs. (in Lakhs)
A CONTINUING OPERATIONS			
1 Revenue from operations (gross)	3,853.91	5,704.60	2,941.29
2 Other income	2.00	78.90	12.58
3 Total revenue (1+2)	3,855.91	5,783.50	2,953.88
4 Expenses			
(a) Cost of materials consumed	1,635.77	3,081.17	1,530.07
(b) Purchases of stock-in-trade	635.65	321.88	99.89
(c) Changes in inventories of finished goods, work-in-progress	237.97	-42.74	338.34
(d) Other Operating Expenses	222.51	522.12	249.05
(e) Employee benefits expense	332.52	459.64	249.35
(f) Finance costs	283.26	580.92	292.71
(f) Depreciation and amortisation expense	123.30	245.46	160.77
(g) Other expenses	314.10	600.84	152.25
Total expenses	3,785.08	5,769.28	3,072.43
5 Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)	70.83	14.22	-118.56
6 Exceptional items			
7 Profit / (Loss) before extraordinary items and tax (5 ± 6)	70.83	14.22	-118.56
8 Extraordinary items	14.04	6.76	
9 Profit / (Loss) before tax (7 ± 8)	56.78	7.46	-118.56
10 Tax expense:			
(a) Current tax expense for current year	23.06	14.91	
(b) (Less): MAT credit (where applicable)			
(c) Current tax expense relating to prior years			
(d) Net current tax expense	23.06	14.91	
(e) Deferred tax	-2.89	-0.21	
	20.17	14.70	
11 Profit / (Loss) from continuing operations (9 ± 10)	36.62	-7.24	-118.56
B DISCONTINUING OPERATIONS			
12.i Profit / (Loss) from discontinuing operations (before tax)			
12.ii Gain / (Loss) on disposal of assets / settlement of liabilities attributable to the discontinuing operations			
12.iii Add / (Less): Tax expense of discontinuing operations			
(a) on ordinary activities attributable to the discontinuing operations			
(b) on gain / (loss) on disposal of assets / settlement of liabilities			
13 Profit / (Loss) from discontinuing operations (12.i ± 12.ii ± 12.iii)			
14 Profit / (Loss) for the year (11 ± 13)	36.62	-7.24	-118.56
15.i Earnings per share (23360764 Shares of Rs. 10/- each):			
(a) Basic			
(i) Continuing operations	0.16	-0.03	-0.51
(ii) Total operations	0.16	-0.03	-0.51
(b) Diluted			
(i) Continuing operations	0.16	-0.03	-0.51
(ii) Total operations	0.16	-0.03	-0.51
15.ii Earnings per share (23360764 Shares of Rs. 10/- each):			
(a) Basic			
(i) Continuing operations	0.16	-0.03	-0.51
(ii) Total operations	0.16	-0.03	-0.51
(b) Diluted			
(i) Continuing operations	0.16	-0.03	-0.51
(ii) Total operations	0.16	-0.03	-0.51



Notes:

1. The Above Financial Results and Statement of Assets and Liabilities were prepared as per Accounting Standards and reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 13th November, 2020
2. The Results for the half year ended on 30th September, 2020 are audited by the Statutory Auditors of the company in compliance with the regulation 33 of SEBI (LODR) Regulations, 2015
3. The Earning Per Share (EPS) has been computed in accordance with the AS-20
4. The consolidated accounts have been prepared as per AS-21
5. List of Subsidiary as on 30th September 2020
Name of the Entity : Dr. Smiths Biotech Private Limited
Relationship : Subsidiary
Country of Incorporation : India
% of Ownership : 100%
6. Other Income for the year ended on 30.09.2020 includes Interest on Fixed Deposits, Income from Export benefits & Other Misc. Income
7. The Status of Investors Complaints during the half year ended on 30.09.2020 is as under
Pending at the beginning of the above period: NIL
Received during the above period: NIL
Disposed during the above period: NIL
Remaining unsolved at the end of the above period: NIL
8. Figures of previous year/Period have been regrouped/recasted wherever necessary, in order to make them comparable.
9. The company is primarily engaged in the business of Pharmaceuticals-which is single reportable segment for the half year/ year ended 30.09.2020 hence no separate separate segment reporting is given as per AS-17

Date: 13/11/2020
Place: Pune



For Cian Healthcare Limited

Suraj Zanwar
Managing Director
DIN: 01304850

CIAN HEALTHCARE LIMITED
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308
CIN: L24233PN2003PLC017563

STATEMENT OF STANDALONE BALANCESHEET AS AT 30.09.2020

Particulars		As at September 30,2020	As at March 31, 2020
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	2,336.08	2,336.08
	(b) Reserves and surplus	3,655.31	3,618.69
	(c) Money received against share warrants		
2	Share application money pending allotment		
3	Non-current liabilities		
	(a) Long-term borrowings	2,542.70	2,449.04
	(b) Deferred tax liabilities (net)	132.25	135.14
	(c) Other long-term liabilities	97.55	97.55
	(d) Long-term provisions	71.60	62.14
4	Current liabilities		
	(a) Short-term borrowings	2,762.80	2,694.19
	(b) Trade payables	1,537.55	1,598.58
	(c) Other current liabilities	388.55	426.27
	(d) Short-term provisions	51.30	40.10
	TOTAL	13,575.68	13,457.80
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets		
	(i) Tangible assets	1,969.11	2,077.52
	(ii) Intangible assets	-	-
	(iii) Capital work-in-progress	2,503.69	2,480.18
	(iv) Intangible assets under development		
	(v) Fixed assets held for sale		
	(b) Non-current investments	708.84	708.84
	(c) Deferred tax assets (net)		
	(d) Long-term loans and advances	1,912.42	2,082.97
	(e) Other non-current assets	669.86	791.89
2	Current assets		
	(a) Current investments	-	-
	(b) Inventories	2,037.24	1,971.63
	(c) Trade receivables	2,515.06	1,994.61
	(d) Cash and cash equivalents	297.94	301.85
	(e) Short-term loans and advances	488.23	609.79
	(f) Other current assets	473.29	438.51
	TOTAL	13,575.68	13,457.80



CIAN HEALTHCARE LIMITED
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308
CIN: L24233PN2003PLC017563

STATEMENT OF STANDALONE CASHFLOW AS AT 30.09.2020

Particulars	As at September 30,2020	As at March 31, 2020
Cash Flow from operating activities		
Net Profit after tax	36.62	-7.24
Adjustment for:		
- Depreciation and amortization expense	123.30	245.46
- (Profit) / Loss on Sale/Disposal of assets		-
- Interest Expenses	255.05	570.76
- Interest & Dividend received	-5.72	-10.86
- Deferred Tax Liability	-2.89	-0.21
Operating profit before working capital changes	406.35	797.90
(Increase) / Decrease in Other Non Current asset	122.02	-201.65
(Increase) / Decrease in Inventories	-65.61	-376.71
(Increase) / Decrease in Trade receivables	-520.44	227.60
(Increase) / Decrease in Other Current Assets	-34.78	-1,546.41
(Increase) / Decrease in Deferred Tax Asset		
(Increase) / Decrease in other financial assets	121.56	-7.92
Increase / (Decrease) in Provisions	20.65	-0.07
Increase / (Decrease) in Trade Payables	-61.04	7.68
Increase / (Decrease) in Other Financial Liabilities/Short Term Borrowing		
Increase / (Decrease) in Deferred tax liabilities		
Increase / (Decrease) in Other Current Liabilities	-37.72	175.80
Cash generated from operations	-49.00	-923.79
Taxes paid		
Net cash from operating activities	-49.00	-923.79
Cash flow from Investing activities		
Purchase of fixed assets	-14.89	-25.33
Proceeds from sale of fixed assets/Subsidy	0	50.00
(Increase) / Decrease in Capital Work in Progress	-23.5171	-1,843.06
Interest & Dividend received	5.72	10.86
Purchases of Shares of Dr. Smiths Biotech Private Ltd.	0	-708.84
Proceeds / (Repayment) of Other Financial Assets		-
Net Cash flow from investing activities	-32.68	-2,516.36
Cash flow from financing activities		
Proceeds from issuance of Share Capital including share premium	0	3,791.76
Proceeds from long term borrowings	93.66	162.57
Proceeds / (Repayment) from / of short term borrowings (Above)	68.61	114.95
Proceeds from Share Application Money		
Dividend Paid including dividend distribution tax		
Proceeds / (Repayment) for Other Financial Assets	170.56	10.41
Interest paid	-255.05	-570.76
Net Cash flow from Financing Activities	77.78	3,508.93
Increase / (Decrease) in cash and cash equivalents	-3.91	68.77
Cash and cash equivalents at beginning of the year	301.85	233.08
Cash and cash equivalents at end of the year	297.94	301.85





**Limited Review Report on unaudited half yearly and year to date Consolidated Financial Results of the
Cian Healthcare Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

The Board of Directors
Cian Healthcare Limited


1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Cian Healthcare Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax for the half year ended 30 September 2020 and year to date results for the period from 01 April 2020 to 30 September 2020 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the following entities:
 - Holding Company**
 - Cian Healthcare Limited
 - Subsidiary Company**
 - Dr. Smiths Biotech Private Limited
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted



in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results and other financial information of subsidiary included in the Statement, whose interim financial results and other financial information reflects total assets of Rs 2325.09 lakhs as at 30 September 2020 and total revenues of Rs 47.79 lakhs, total net loss after tax of Rs. 144.39 lakhs, for the half year ended 30 September 2020, and cash outflows (net) of Rs. 30.20 lakhs for the period from 01 April 2020 to 30 September 2020, as considered in the consolidated unaudited financial results. These interim financial results and other financial information have been reviewed by other auditor whose report has been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.

For Agarwal Mahesh K. & Co.
Chartered Accountants



CA Sunny Boundia
Partner
FRN: 008007C
Membership No. 164172
Date: 13.11.2020
UDIN:- 20164172AAAAABA8968
Pune



CIAN HEALTHCARE LIMITED
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308
CIN: L24233PN2003PLC017563

STATEMENT OF CONSOLIDATED PROFIT AND LOSS FOR THE HALF YEAR ENDED ON 30.09.2020

	Particulars	For the half year ended September 30, 2020	For the year ended March 31, 2020	For the half year ended September 30, 2019
		Unaudited	Audited	Unaudited
		Rs. (in Lakhs)	Rs. (in Lakhs)	Rs. (in Lakhs)
A	CONTINUING OPERATIONS			
1	Revenue from operations (gross)	3,889.47	5,708.83	2,941.29
2	Other income	9.25	86.27	19.39
3	Total revenue (1+2)	3,898.73	5,795.10	2,960.69
4	Expenses			
	(a) Cost of materials consumed	1,637.83	3,081.17	1,530.07
	(b) Purchases of stock-in-trade	646.97	320.94	99.89
	(c) Changes in inventories of finished goods, work-in-progress and stock	231.28	-42.74	338.34
	(d) Other Operating Expenses	222.51	541.51	249.99
	(e) Employee benefits expense	333.56	467.68	257.49
	(f) Finance costs	356.15	712.01	359.39
	(g) Depreciation and amortisation expense	223.68	444.87	160.77
	(g) Other expenses	319.81	614.82	167.11
	Total expenses	3,971.79	6,140.26	3,163.06
5	Profit / (Loss) before exceptional and extraordinary items and tax	-73.06	-345.16	-202.37
6	Exceptional items			
7	Profit / (Loss) before extraordinary items and tax (5 + 6)	-73.06	-345.16	-202.37
8	Extraordinary items	14.55	6.76	
9	Profit / (Loss) before tax (7 + 8)	-87.61	-351.92	-202.37
10	Tax expense:			
	(a) Current tax expense for current year	23.06	14.91	
	(b) (Less): MAT credit (where applicable)			
	(c) Current tax expense relating to prior years			
	(d) Net current tax expense	23.06	14.91	
	(e) Deferred tax	-2.89	11.41	
		20.17	26.32	
11	Profit / (Loss) from continuing operations (9 + 10)	-107.77	-378.24	-202.37
B	DISCONTINUING OPERATIONS			
12.i	Profit / (Loss) from discontinuing operations (before tax)			
12.ii	Gain / (Loss) on disposal of assets / settlement of liabilities attributable to the discontinuing operations			
12.iii	Add / (Less): Tax expense of discontinuing operations (a) on ordinary activities attributable to the discontinuing operations (b) on gain / (loss) on disposal of assets / settlement of liabilities			
13	Profit / (Loss) from discontinuing operations (12.i + 12.ii + 12.iii)			
14	Profit / (Loss) for the year (11 + 13)	-107.77	-378.24	-202.37
15.i	Earnings per share (23360764 Shares of Rs. 10/- each):			
	(a) Basic	-0.46	-1.62	-0.87
	(i) Continuing operations	-0.46	-1.62	-0.87
	(ii) Total operations			
	(b) Diluted			
	(i) Continuing operations			
	(ii) Total operations			
15.ii	Earnings per share (23360764 Shares of Rs. 10/- each):			
	(a) Basic	-0.46	-1.62	-0.87
	(i) Continuing operations	-0.46	-1.62	-0.87
	(ii) Total operations			
	(b) Diluted			
	(i) Continuing operations			
	(ii) Total operations			



Notes:

1. The Above Financial Results and Statement of Assets and Liabilities were prepared as per Accounting Standards and reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 13th November, 2020
2. The Results for the half year ended on 30th September, 2020 are audited by the Statutory Auditors of the company in compliance with the regulation 33 of SEBI (LODR) Regulations, 2015
3. The Earning Per Share (EPS) has been computed in accordance with the AS-20
4. The consolidated accounts have been prepared as per AS-21
5. List of Subsidiary as on 30th September 2020
Name of the Entity : Dr. Smiths Biotech Private Limited
Relationship : Subsidiary
Country of Incorporation : India
% of Ownership : 100%
6. Other Income for the year ended on 30.09.2020 includes Interest on Fixed Deposits, Income from Export benefits & Other Misc. Income
7. The Status of Investors Complaints during the half year ended on 30.09.2020 is as under
Pending at the beginning of the above period: NIL
Received during the above period: NIL
Disposed during the above period: NIL
Remaining unsolved at the end of the above period: NIL
8. Figures of previous year/Period have been regrouped/recasted wherever necessary, in order to make them comparable.
9. The company is primarily engaged in the business of Pharmaceuticals which is single reportable segment for the half year/ year ended 30.09.2020 hence no separate separate segment reporting is given as per AS-17

Date: 13/11/2020
Place: Pune

For Cian Healthcare Limited




Suraj Zanwar
Managing Director
DIN: 01304850

CIAN HEALTHCARE LIMITED
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308
CIN: L24233PN2003PLC017563

STATEMENT OF CONSOLIDATED BALANCESHEET AS AT 30.09.2020

Particulars		As at September 30,2020	As at March 31, 2020
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	2,336.08	2,336.08
	(b) Reserves and surplus	3,375.23	3,483.00
	(c) Money received against share warrants		
2	Share application money pending allotment		
3	Non-current liabilities		
	(a) Long-term borrowings	4,606.64	4,583.76
	(b) Deferred tax liabilities (net)	171.4838728	174.3741014
	(c) Other long-term liabilities	176.56	166.46
	(d) Long-term provisions	71.60	62.14
4	Current liabilities		
	(a) Short-term borrowings	2,884.67	2,731.86
	(b) Trade payables	1,566.23	1,624.14
	(c) Other current liabilities	388.93	427.35
	(d) Short-term provisions	59.15	53.79
	TOTAL	15,636.57	15,642.95
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets		
	(i) Tangible assets	3,734.35	3,942.60
	(ii) Intangible assets		
	(iii) Capital work-in-progress	2,526.11	2,502.59
	(iv) Intangible assets under development		
	(v) Fixed assets held for sale		
	(b) Non-current investments	488.84	488.84
	(c) Deferred tax assets (net)		
	(d) Long-term loans and advances	2,061.23	2,231.79
	(e) Other non-current assets	669.86	791.89
2	Current assets		
	(a) Current investments		
	(b) Inventories	2,062.92	1,971.63
	(c) Trade receivables	2,540.92	1,998.56
	(d) Cash and cash equivalents	411.25	445.35
	(e) Short-term loans and advances	712.01	831.19
	(f) Other current assets	429.08	438.51
	TOTAL	15,636.57	15,642.95



CIAN HEALTHCARE LIMITED
MILKAT NO.3339, BLOCK NO.1 FROM SOUTH SIDE,
C.S.NO.227/2+3A,HARPALE PARK,OPP.BERGER PAINT
PHURSUNGI, TAL. HAVELI,DIST. PUNE-412308
CIN: L24233PN2003PLC017563

STATEMENT OF CONSOLIDATED CASHFLOW AS AT 30.09.2020

Particulars	As at September 30,2020	As at March 31, 2020
Cash Flow from operating activities		
Net Profit after tax	-107.77	-378.76
Adjustment for:		
- Depreciation and amortization expense	223.68	444.87
- (Profit) / Loss on Sale/Disposal of assets	0	-
- Interest Expenses	327.91	701.81
- Interest & Dividend received	-12.98	-18.23
- Deferred Tax Liability	-2.89	-0.21
Operating profit before working capital changes	427.95	749.49
	0	-
(Increase) / Decrease in Other Non Current asset	122.02	-201.65
(Increase) / Decrease in Inventories	-91.29	-376.71
(Increase) / Decrease in Trade receivables	-542.36	227.09
(Increase) / Decrease in Other Current Assets	-37.15	-1,542.86
(Increase) / Decrease in Deferred Tax Asset	0	-
(Increase) / Decrease in other financial assets	121.56	-7.92
Increase / (Decrease) in Provisions	14.81	11.01
Increase / (Decrease) in Trade Payables	-57.91	224.03
Increase / (Decrease) in Other Financial Liabilities/Short Term Borrowing	84.2025	-108.73
Increase / (Decrease) in Deferred tax liabilities	0	11.62
Increase / (Decrease) in Other Current Liabilities	5.78	175.17
	0	-
Cash generated from operations	47.63	-839.47
	0	-
Taxes paid	0	-
Net cash from operating activities	47.63	-839.47
	0	-
Cash flow from Investing activities	0	-
Purchase of fixed assets	-15.43	-96.41
Proceeds from sale of fixed assets/Subsidy	0	50.00
(Increase) / Decrease in Capital Work in Progress	-23.5171	-1,864.44
Interest & Dividend received	12.98	18.23
Purchases of Shares of Dr. Smiths Biotech Private Ltd.	0	-708.84
Proceeds / (Repayment) of Other Financial Assets	0	-142.62
Net Cash flow from investing activities	-25.97	-2,744.08
	0	-
Cash flow from financing activities	0	-
Proceeds from issuance of Share Capital including share premium	0	3,791.76
Proceeds from long term borrowings	22.87	813.83
Proceeds / (Repayment) from / of short term borrowings (Above)	78.72	-227.51
Proceeds from Share Application Money	0	-
Dividend Paid including dividend distribution tax	0	-
Proceeds / (Repayment) for Other Financial Assets	170.56	10.41
Interest paid	-327.91	-701.81
Net Cash flow from Financing Activities	-55.76	3,686.68
	0	-
Increase / (Decrease) in cash and cash equivalents	-34.10	103.13
Cash and cash equivalents at beginning of the year	445.35	342.22
Cash and cash equivalents at end of the year	411.25	445.35

